Recently Intellia Therapeutics in collaboration with Regeneron announced some promising results for their phase I trial using their lead product NTLA-2001, for an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis. In this video I discuss the science behind in vivo CRISPR gene editing and what this means more generally for the CRISPR field or as Intellia phrase it the #NewEraOfMedicine.
TIMESTAMPS
Intro - 00:00
Intellia & CRISPR-Cas9 genome editing - 00:35
NTLA-2001 - 02:30
#NewEraOfMedicine? - 08:00
REFERENCES
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis DOI: 10.1056/NEJMoa2107454 [ Ссылка ]
Check out @LongevityScienceNews to see their latest videos!
Icons in intro; "[ Ссылка ] vector created by freepik - www.freepik.com
Intellia and the #NewEraOfMedicine (in vivo CRISPR)
Теги
intellia therapeuticsstock marketgene editingntla stockcrispr stockntla-2001crispr cas9attr amyloidosisprotein misfoldingsgRNAnobel prizescience behind crisprregeneron therapeuticsregeneronbiochemistrysciencehealthfuture of crisprin vivo crisprlipid nanoparticlesintellianeweraoftherapeuticscrispr therapeuticsjennifer doudnacrsp stockhuman genome editingmonogenic diseasebusiness news
